120 related articles for article (PubMed ID: 11714476)
1. [Acute hepatitis induced by valsartan].
Reñé JM; Buenestado J; Sesé E; Miñana JM
Med Clin (Barc); 2001 Nov; 117(16):637-8. PubMed ID: 11714476
[No Abstract] [Full Text] [Related]
2. Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient.
Kiykim A; Altintas E; Sezgin O; Sezer K; Tiftik N; Akbay E; Seyrek E; Konca K
Am J Gastroenterol; 2003 Feb; 98(2):507. PubMed ID: 12591083
[No Abstract] [Full Text] [Related]
3. Angioedema due to valsartan.
Martínez Alonso JC; Domínguez Ortega FJ; Méndez Alcalde J; Fuentes Gonzalo MJ
Allergy; 2003 Apr; 58(4):367. PubMed ID: 12708991
[No Abstract] [Full Text] [Related]
4. [Biliary stenosis, hepatitis A and valsartan: multifactorial hepatotoxicity in a surgical patient].
Gómez NA; Mejillón JL; Zapatier JA; Vargas PE
Cir Esp; 2006 Mar; 79(3):189-91. PubMed ID: 16545288
[TBL] [Abstract][Full Text] [Related]
5. Nightmares induced by valsartan.
Kastalli S; El AS; Loueslati MH; Daghfous R; Belkahia C
Therapie; 2006; 61(1):81-2. PubMed ID: 16792161
[No Abstract] [Full Text] [Related]
6. [Angioedema and urticarial reaction induced by valsartan].
de la Serna Higuera C
Med Clin (Barc); 2000 Apr; 114(15):599. PubMed ID: 10846683
[No Abstract] [Full Text] [Related]
7. Potential drug interaction between lithium and valsartan.
Leung M; Remick RA
J Clin Psychopharmacol; 2000 Jun; 20(3):392-3. PubMed ID: 10831034
[No Abstract] [Full Text] [Related]
8. Lithium intoxication after valsartan treatment.
Su YP; Chang CJ; Hwang TJ
Psychiatry Clin Neurosci; 2007 Apr; 61(2):204. PubMed ID: 17362443
[No Abstract] [Full Text] [Related]
9. Linear lichenoid drug eruption induced by valsartan.
Gencoglan G; Ceylan C; Kazandi AC
Clin Exp Dermatol; 2009 Oct; 34(7):e334-5. PubMed ID: 19456765
[No Abstract] [Full Text] [Related]
10. Valsartan. Just a second-line antihypertensive drug.
Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
[TBL] [Abstract][Full Text] [Related]
11. Angioedema and photosensitive rash induced by valsartan.
Frye CB; Pettigrew TJ
Pharmacotherapy; 1998; 18(4):866-8. PubMed ID: 9692664
[TBL] [Abstract][Full Text] [Related]
12. Fetal toxic effects and angiotensin-II-receptor antagonists.
Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
[No Abstract] [Full Text] [Related]
13. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.
Fogari R; Zoppi A; Carretta R; Veglio F; Salvetti A;
J Hypertens; 2002 May; 20(5):1007-14. PubMed ID: 12011663
[TBL] [Abstract][Full Text] [Related]
14. Fatal fetal outcome with the combined use of valsartan and atenolol.
Briggs GG; Nageotte MP
Ann Pharmacother; 2001; 35(7-8):859-61. PubMed ID: 11485133
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
[TBL] [Abstract][Full Text] [Related]
16. Second study on valsartan is threatened with retraction over alleged data manipulation.
Mahony C
BMJ; 2013 Aug; 347():f4920. PubMed ID: 23918698
[No Abstract] [Full Text] [Related]
17. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II antagonism in clinical practice: experience with valsartan.
McInnes GT
J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S29-32; discussion S41-3. PubMed ID: 10028951
[TBL] [Abstract][Full Text] [Related]
19. Valsartan-induced angioedema.
Irons BK; Kumar A
Ann Pharmacother; 2003; 37(7-8):1024-7. PubMed ID: 12841812
[TBL] [Abstract][Full Text] [Related]
20. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
Mochizuki S; Dahlöf B; Shimizu M; Ikewaki K; Yoshikawa M; Taniguchi I; Ohta M; Yamada T; Ogawa K; Kanae K; Kawai M; Seki S; Okazaki F; Taniguchi M; Yoshida S; Tajima N;
Lancet; 2007 Apr; 369(9571):1431-1439. PubMed ID: 17467513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
